1314TH(Ethionamide)と1321TH(Prothionamide)の肝障害に関する臨床的研究 : 剤型を同一にした比較研究
スポンサーリンク
概要
- 論文の詳細を見る
The clinical use of prothionamide has been increasing recently because of less frequent gastrointestinal disturbance compared with that of ethionamide. Some workers, however, reported the higher hepatic disturbance during prothionamide treatment than ethionamide treatment. In Japan, the type of preparation of both drugs is different; ethionamide is used as the type of enteric coated tablet and prothionamide is used as the type of sugar coated tablet.<BR>This paper presents the hepatic disturbance during ethionamide or prothionamide treatment by the using the same type of preparation. For a comparative study on hepatic disturbance between ethionamide and prothionamide treatment, the enteric coated granule of both drugs was specially prepared.<BR>The patients who were newly prescribed TH were divided into two groups—ethionamide and prothionamide groups—alternatively. In both groups, daily dose of drug was 0.5g, divided into three equal dose and given after meal. In many cases kanamycin and ethambutol were combined with ethionamide or prothionamide. The hepatic function tests during ethiona mide or prothionamide taeatment were performed 1 to 2 times a month.<BR>The results were as follows;<BR>The elevation of SGOT or SG P T unit more than 40 units was observed among 11 out of 47 cases (23.4%) during ethionamide treatment and among 16 out of 47 cases (34.0%) during prothionamide treatment. The elevation of transaminase activity more than 100 units was seen in 10.6% during ethionamide treatment and 14.9% during prothionamide treatment (Table 1). The hepatic disturbance appeared more frequently among prothionamide group than among ethionamide group, but the difference was statistically not significant.<BR>The time of the hepatic disturbance first appeared is shown in Tables 2 and 3. The hepatic disturbance during TH treatment appeared within 6 months. The difference in the incidence rate of the hepatic disturbance was not seen between 1 to 3 months and 4 to 6 months.<BR>The relationship between the incidence of the hepatic disturbance and the background factors of the patients was studied (Table 4), but no relation was found.<BR>In summary, <BR>the hepatic disturbance was seen more frequently during prothionamide treatment than during ethionamide treatment, but the difference was not significant.
- 日本結核病学会の論文
著者
関連論文
- 実験結核症に対する4,4-diisoamyloxy-thiocarbanilide(lsoxyl)の抗結核作用について
- 薬剤耐性菌感染に関する研究
- STC [2, 3-dipheny1-5-thienyl-(2)-tetrazolium chloride] の応用による結核菌発育の早期判定に関する研究 : 第4報STC含有培地の分離培養への応用に関する研究
- STC [2, 3-diphenyl-5-thienyl-(2)-tetrazolium chloride] の応用による結核菌発育の早期判定に関する研究 : 第3報 STC含有培地に関する研究
- Tuberactinomycin-Nの臨床成績
- Rifampicin耐性結核菌の毒力に関する実験的研究 (予報)
- Tuberactinomycinの臨床成績
- 1314TH(Ethionamide)と1321TH(Prothionamide)の肝障害に関する臨床的研究 : 剤型を同一にした比較研究
- STC[2,3-dipheny1-5-thienyl-(2)-tetrazoliumchloride]の応用による結核菌発育の早期判定に関する研究 : 第1報STCの応用による結核菌発育の早期判定に関する基礎的研究
- CSカプセルの保存によるCSの力価の安定性に関する研究
- 薬剤耐性菌感染に関する研究
- Kanamycin耐性菌に対するViomycinおよびCapreomycinの抗菌力KMとVM, CPMの交叉耐性に関する研究
- 抗結核薬の副作用防止に関する研究 : 特にPantethineの効果について
- リンパ節結核に対するRifampicinの治療効果に関する研究
- 薬剤耐性菌感染に関する研究